Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.27 - $4.08
Previous CloseN/A
Volume16.21M
Average Volume (3M)1.24M
Market Cap
$605.65M
Enterprise Value$268.49M
Total Cash (Recent Filing)$100.95M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Nov 06, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding171,572,500
10 Day Avg. Volume835,592
30 Day Avg. Volume1,239,502
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-731.58
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$12.67Price Target Upside258.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive pivotal topline results were announced from the COMPANION-002 study of tovecimig in combination with paclitaxel in patients with advanced BTC.
Market PotentialThe landscape in 2L BTC is barren, with room for a new standard of care to obtain meaningful market share in the majority of patients without available targeted therapy.
Regulatory OpportunitiesThe company is considering applying for Breakthrough Designation, which would allow more frequent discussions with the FDA.
Bears Say
Financial ValuationThe valuation is predicated on a ~3x EV/5-year forward sales estimate, which is a premium to the small cap peer group trading at ~1x.
Operational ChallengesManagement confirmed the trial is proceeding smoothly without any operational issues that could explain the slow event accrual rate.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.27 and its highest was $4.08 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $605.65M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 54 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.016.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 171,572,500 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 23.704%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
Compass Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (258.92% Upside)
$12.67 (258.92% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 547.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.33%
12-Months-Change
Fundamentals
Return on Equity
-51.84%
Trailing 12-Months
Asset Growth
-25.01%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics (CMPX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody therapeutics. The company operates in the biopharmaceutical sector, concentrating on innovative treatments that target complex diseases such as cancer and autoimmune disorders. Compass Therapeutics leverages its proprietary StitchMabsTM technology, which enables the development of bispecific and multispecific antibody therapeutics aimed at enhancing immune system response and improving patient outcomes.
CMPX Earnings Call
Q2 2025
0:00 / 0:00
CMPX Stock 12 Month Forecast
Average Price Target
$12.67
▲(258.92% Upside)
Technical Analysis
Verastem
―
Palvella Therapeutics
―
Atea Pharmaceuticals
―
Humacyte
―
Candel Therapeutics
―
Ownership Overview
27.24% Insiders
6.73% Mutual Funds
0.02% Other Institutional Investors
59.80% Public Companies and
Individual Investors